Method of treating toxemia

Patent metadata

Field	Value
Publication number	US-9023344-B2
Application number	US-201314037696-A
Country	US
Kind code	B2
Filing date	Sep 26, 2013
Priority date	Mar 13, 2008
Publication date	May 5, 2015
Grant date	May 5, 2015

Abstract

A therapeutic agent for the treatment of toxemia, preeclampsia and eclampsia and a method for preparing the therapeutic agent are disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or by other methods. Further, a method of using the presence of chymotrypsin in the maternal GI tract as a biomarker, to determine the likelihood of developing preeclampsia, a pregnancy induced hypertension, and eclampsia/toxemia is disclosed.

First claim

What is claimed is:

1. A method for treating an individual exhibiting toxemia, the method comprising administering a therapeutically effective amount of a pharmaceutical preparation comprising digestive enzymes to the individual, wherein the digestive enzymes comprise an amylase, a lipase, a protease, or a combination thereof, whereby toxemia is treated.

2. The method of claim 1 , wherein the protease comprises chymotrypsin or trypsin.

3. The method of claim 1 , wherein the digestive enzymes are provided as pancreatin.

4. The method of claim 1 , wherein the digestive enzymes are obtained from a source selected from the group consisting of animal enzymes, plant enzymes, synthetic enzymes, and a combination thereof.

5. The method of claim 1 , wherein the pharmaceutical preparation is manufactured using a technology selected from the group consisting of enteric coating, lipid encapsulation, direct compression, dry granulation, wet granulation, and a combination thereof.

6. The method of claim 1 , wherein the pharmaceutical preparation is administered orally via a dosage formulation selected from the group consisting of: pills, tablets, capsules, microcapsules, mini-capsules, time released capsules, mini-tabs, sprinkles, and a combination thereof.

7. The method of claim 1 , wherein the amount of amylase ranges from 10,000 to 60,000 USP units/dose.

8. The method of claim 1 , wherein the amount of protease ranges from 10,000 to 70,000 USP units/dose.

9. The method of claim 1 , wherein the amount of lipase ranges from 4,000 to 30,000 USP units/dose.

10. The method of claim 3 , wherein the amount of pancreatin ranges from 2,000 to 6,000 USP units/dose.

11. The method of claim 2 , wherein the amount of chymotrypsin ranges from 2 to 5 mg/dose.

12. The method of claim 2 , wherein the amount of trypsin ranges from 60 to 100 mg/dose.

Assignees

• Curemark Llc

Inventors

• Fallon Joan M

Classifications

• A61P9/12

  Antihypertensives · CPC title

• A61K38/48

  acting on peptide bonds (3.4) · CPC title

• A61K38/54 Primary

  Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53 · CPC title

• C12Y302/01

  Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1) · CPC title

• A61K38/4873

  Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H · CPC title